AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35768575 — intervention group
Group type: COMPARATOR
Intervention: Other consumer-grade fat measurement devices
Number of subjects: 134
Study 35768859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept 1.25 mg (0.05 ml) administered by intravitreal injection monthly for 6 months
Number of subjects: 40
Study 35769080 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Programme (EP) based on outreach visits
Number of subjects: 587
Study 35769080 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) with no Educational Programme
Number of subjects: 587
Study 35769244 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic once-daily tacrolimus
Number of subjects: 144
Study 35769360 — intervention group
Group type: EXPERIMENTAL
Intervention: DISE-guided CPAP titration
Number of subjects: 24
Study 35769360 — intervention group
Group type: COMPARATOR
Intervention: CSC CPAP titration
Number of subjects: 24
Study 35769368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase treatment
Number of subjects: 503
Study 35769368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alteplase treatment)
Number of subjects: 503
Study 35769451 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support grant (maximum: $750)
Number of subjects: 0
Study 35769451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-conference survey for applicants
Number of subjects: 0
Study 35769451 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-conference survey for recipients
Number of subjects: 0
Study 35770218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion-FFR
Number of subjects: 148
Study 35770218 — intervention group
Group type: COMPARATOR
Intervention: CT-FFR
Number of subjects: 148
Study 35770218 — intervention group
Group type: COMPARATOR
Intervention: OCT-FFR
Number of subjects: 148
Study 35770220 — intervention group
Group type: EXPERIMENTAL
Intervention: V-LAP system for left atrial pressure monitoring
Number of subjects: 5
Study 35770681 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 110
Study 35770702 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory comic intervention
Number of subjects: 0
Study 35770988 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote telehealth intervention (using computers or phones)
Number of subjects: 21
Study 35771029 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0
Study 35771029 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to vigorous-intensity physical activity (MVPA)
Number of subjects: 0
Study 35771029 — intervention group
Group type: EXPERIMENTAL
Intervention: Late timing of physical activity
Number of subjects: 0
Study 35771029 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity clustering by intensity and time of day
Number of subjects: 0
Study 35771259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib 500 mg/day
Number of subjects: 0
Study 35771259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib (30-1400 mg)
Number of subjects: 0
Study 35771259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib (500 mg and 1000 mg)
Number of subjects: 0
Study 35771259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib
Number of subjects: 0
Study 35771301 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept combined with docetaxel (75 mg/m²)
Number of subjects: 12
Study 35771301 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m²)
Number of subjects: 12
Study 35771568 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor
Number of subjects: 0
Study 35771572 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased default number of opioid doses from 30 to 12 in pediatric otolaryngology patients post-intervention.
Number of subjects: 237
Study 35771573 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (37.5 mg to 300 mg daily for up to 12 weeks)
Number of subjects: 416
Study 35771573 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release
Number of subjects: 416
Study 35771832 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional multitask training (TMT)
Number of subjects: 25
Study 35771832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TMT and video game multitask training (VGMT)
Number of subjects: 25
Study 35771832 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game multitask training (VGMT)
Number of subjects: 25
Study 35771872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot-based decision aid combined with screening reminder letters and HPV self-sampling kits.
Number of subjects: 4000
Study 35771872 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (reminder letters and HPV self-sampling kits).
Number of subjects: 4000
Study 35771992 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational physical activity (PA) prior to and during pregnancy
Number of subjects: 298
Study 35771992 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational physical activity (PA) during pregnancy
Number of subjects: 298
Study 35772015 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35772170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rondoraptivon pegol (3 mg subcutaneously on days 1, 4, and 7, followed by 6 to 9 mg weekly until day 28)
Number of subjects: 5
Study 35772170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rondoraptivon pegol
Number of subjects: 5
Study 35772177 — intervention group
Group type: EXPERIMENTAL
Intervention: O3AEE (omega-3-acid ethyl esters) 2 g/day
Number of subjects: 13864
Study 35772177 — intervention group
Group type: COMPARATOR
Intervention: Non-O3AEE (control group)
Number of subjects: 13864
Study 35772258 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate internalizing and externalizing symptoms (with low alcohol misuse)
Number of subjects: 1689
Study 35772258 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest internalizing and externalizing symptoms (with highest social disconnection)
Number of subjects: 1689
Study 35772258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest internalizing symptoms and low externalizing (with highest social connection and alcohol misuse)
Number of subjects: 1689
Study 35772392 — intervention group
Group type: EXPERIMENTAL
Intervention: High stress hyperglycemia ratio (SHR)
Number of subjects: 6892
Study 35772392 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding SHR to the original model
Number of subjects: 6892
Study 35772417 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP (tenofovir disoproxil 245 mg and emtricitabine 200 mg, one pill per day)
Number of subjects: 3065
Study 35772417 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand PrEP (following IPERGAY dosing recommendation)
Number of subjects: 3065
Study 35772417 — intervention group
Group type: COMPARATOR
Intervention: Daily PrEP
Number of subjects: 3065
Study 35772417 — intervention group
Group type: COMPARATOR
Intervention: On-demand PrEP
Number of subjects: 3065
Study 35772429 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR2554 (350 mg twice daily)
Number of subjects: 113
Study 35772429 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR2554 (various doses)
Number of subjects: 113
Study 35772429 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR2554 (all doses)
Number of subjects: 113
Study 35772805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium administration (20 and 120 minutes)
Number of subjects: 95
Study 35772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with moderate to severe ACE
Number of subjects: 36
Study 35772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term relapse assessment
Number of subjects: 36
Study 35772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term relapse assessment
Number of subjects: 36
Study 35772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-based functional MRI (fMRI)
Number of subjects: 36
Study 35772833 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva cortisol and blood samples
Number of subjects: 36
Study 35772852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular enzyme replacement therapy (ERT) with cerliponase alfa
Number of subjects: 28
Study 35772853 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 24/26 mg twice a day
Number of subjects: 445
Study 35772855 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy heart syndrome (pleasant emotional events)
Number of subjects: 910
Study 35772855 — intervention group
Group type: COMPARATOR
Intervention: Broken heart syndrome (negative emotional events)
Number of subjects: 910
Study 35772857 — intervention group
Group type: EXPERIMENTAL
Intervention: HM3 LVAD
Number of subjects: 485
Study 35773299 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ventilation in prone position
Number of subjects: 28
Study 35773299 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation in prone position
Number of subjects: 28
Study 35773299 — intervention group
Group type: COMPARATOR
Intervention: Supine position (control for invasive ventilation)
Number of subjects: 28
Study 35773299 — intervention group
Group type: COMPARATOR
Intervention: Supine position (control for non-invasive ventilation)
Number of subjects: 28
Study 35773354 — intervention group
Group type: EXPERIMENTAL
Intervention: Long chewing time (brown rice: 41s/bite; chickpeas: 37s/bite)
Number of subjects: 26
Study 35773354 — intervention group
Group type: COMPARATOR
Intervention: Short chewing time (brown rice: 23s/bite; chickpeas: 20s/bite)
Number of subjects: 26
Study 35773363 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab (ADX) combined with S-1 plus cisplatin (SP)
Number of subjects: 16
Study 35773363 — intervention group
Group type: EXPERIMENTAL
Intervention: Andecaliximab (ADX) combined with S-1 plus oxaliplatin (SOX)
Number of subjects: 16
Study 35773640 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Number of subjects: 200
Study 35773649 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal gait group
Number of subjects: 1600
Study 35773649 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal gait group
Number of subjects: 1600
Study 35774109 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum, plasma, saliva, and cerebrospinal fluid (CSF) samples from 8 healthy volunteers
Number of subjects: 15
Study 35774109 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum and CSF samples collected at 13 timepoints over a 24-h period after catheter placement from 7 healthy volunteers
Number of subjects: 15
Study 35774470 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiome characteristics in lung cancer patients
Number of subjects: 61
Study 35774470 — intervention group
Group type: COMPARATOR
Intervention: Healthy people (control group)
Number of subjects: 61
Study 35774932 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based, respondent-driven sampling (RDS) survey with HCV screening and immediate treatment
Number of subjects: 554
Study 35775211 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer therapy with physical activity (PA) participation
Number of subjects: 110
Study 35775211 — intervention group
Group type: COMPARATOR
Intervention: Breast cancer therapy without physical activity (inactive)
Number of subjects: 110
Study 35775211 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment physical activity scores
Number of subjects: 110
Study 35775211 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment physical activity scores after three months of BC therapy
Number of subjects: 110
Study 35775211 — intervention group
Group type: COMPARATOR
Intervention: Six-minute walk distance (6MWD) pre-treatment
Number of subjects: 110
Study 35775211 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walk distance (6MWD) post-treatment
Number of subjects: 110
Study 35775211 — intervention group
Group type: COMPARATOR
Intervention: Left ventricular ejection fraction (LVEF) pre-treatment
Number of subjects: 110
Study 35775211 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) post-treatment
Number of subjects: 110
Study 35775319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 0
Study 35775319 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35775373 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 0
Study 35775390 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34 cell therapy
Number of subjects: 30
Study 35775390 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 30
Study 35775417 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-Commissural Alignment Technique for Transcatheter Aortic Valve Replacement using the ACURATE Neo Valve
Number of subjects: 0
Study 35776072 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib 40 mg b.i.d.
Number of subjects: 303
Study 35776072 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (various doses from 10 to 200 mg b.i.d. or 40 to 200 mg q.d.)
Number of subjects: 303
Study 35776131 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal gown and glove use for all patient contact
Number of subjects: 21845
Study 35776131 — intervention group
Group type: COMPARATOR
Intervention: Standard practice for glove and gown use (control)
Number of subjects: 21845
Study 35776144 — intervention group
Group type: EXPERIMENTAL
Intervention: No-stent strategy (SCBA followed by DCB)
Number of subjects: 984
Study 35776144 — intervention group
Group type: COMPARATOR
Intervention: Conventional DES
Number of subjects: 984
Study 35776144 — intervention group
Group type: COMPARATOR
Intervention: BO-stent
Number of subjects: 984
Study 35776144 — intervention group
Group type: COMPARATOR
Intervention: DCB-only
Number of subjects: 984
Study 35776185 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 50 mg once daily
Number of subjects: 34
Study 35776185 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg once daily
Number of subjects: 34
Study 35776199 — intervention group
Group type: EXPERIMENTAL
Intervention: ET019003 T cells (autologous CD19-directed AbTCR T cells)
Number of subjects: 12
Study 35776242 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional analgesia (transversus abdominis plane and rectus sheath block)
Number of subjects: 113
Study 35776242 — intervention group
Group type: EXPERIMENTAL
Intervention: External oblique intercostal block
Number of subjects: 113
Study 35776242 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 113
Study 35776269 — intervention group
Group type: EXPERIMENTAL
Intervention: SB5-HC (40 mg/0.4 ml)
Number of subjects: 188
Study 35776269 — intervention group
Group type: COMPARATOR
Intervention: SB5-LC (40 mg/0.8 ml)
Number of subjects: 188
Study 35776432 — intervention group
Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI
Number of subjects: 10
Study 35776489 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily meditation via Calm app
Number of subjects: 276
Study 35776489 — intervention group
Group type: COMPARATOR
Intervention: Health education podcast control group
Number of subjects: 276
Study 35776519 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological Pupil index (NPi) for the right eye
Number of subjects: 43
Study 35776519 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological Pupil index (NPi) for the left eye
Number of subjects: 43
Study 35776711 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated saline-enhanced radiofrequency (SERF) needle ablation
Number of subjects: 32
Study 35776862 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 0
Study 35776862 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (Control)
Number of subjects: 0
Study 35776862 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (Control)
Number of subjects: 0
Study 35776863 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week telerehabilitation program based on exercises and pain education
Number of subjects: 65
Study 35776863 — intervention group
Group type: COMPARATOR
Intervention: Web-based self-management booklet
Number of subjects: 65
Study 35776909 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR-αβ/CD19-depleted haploidentical HCT
Number of subjects: 51
Study 35776909 — intervention group
Group type: COMPARATOR
Intervention: KIR-favorable haploidentical cohort
Number of subjects: 51
Study 35777109 — intervention group
Group type: EXPERIMENTAL
Intervention: New formula (EF) based on standard formula supplemented with synbiotics, long chain polyunsaturated fatty acids (LC-PUFA) and bovine milk fat globule membranes (MFGM)
Number of subjects: 170
Study 35777109 — intervention group
Group type: EXPERIMENTAL
Intervention: New formula (EF)
Number of subjects: 170
Study 35777109 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 170
Study 35777109 — intervention group
Group type: COMPARATOR
Intervention: Breastfed reference group (BF)
Number of subjects: 170
Study 35777186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for up to 35 cycles (∼2 years)
Number of subjects: 109
Study 35777186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W
Number of subjects: 109
Study 35777697 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) 'check-ups'
Number of subjects: 0
Study 35778065 — intervention group
Group type: EXPERIMENTAL
Intervention: VICTORI (Virtual Immersive Communication Training on Recommending Immunizations) including VR simulations and a smartphone application.
Number of subjects: 134
Study 35778065 — intervention group
Group type: COMPARATOR
Intervention: Smartphone application only (comparison group).
Number of subjects: 134
Study 35778500 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated anti-AAV6 cell-based transduction inhibition (TI) assay
Number of subjects: 0
Study 35778500 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate quality control samples
Number of subjects: 0
Study 35778500 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor samples
Number of subjects: 0
Study 35778519 — intervention group
Group type: EXPERIMENTAL
Intervention: Tattooed skin
Number of subjects: 33
Study 35778519 — intervention group
Group type: COMPARATOR
Intervention: Non-tattooed skin
Number of subjects: 33
Study 35778568 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective agonist of CB2r (JWH133)
Number of subjects: 0
Study 35778568 — intervention group
Group type: COMPARATOR
Intervention: Antioxidants (from phase II clinical trial NCT01495260)
Number of subjects: 0
Study 35778636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab treatment
Number of subjects: 105
Study 35778636 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 TAP ≥ 5% and lack of hyperamplification (HA -)
Number of subjects: 105
Study 35778636 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 positivity, IFNγ-related gene signature, TMB-high status
Number of subjects: 105
Study 35778636 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperamplification (HA +)
Number of subjects: 105
Study 35778674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain after cardiac surgery
Number of subjects: 518
Study 35778674 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative frailty domains (medication use, living situation, mobility, gait speed, Nagi's physical functioning, preoperative HRQL)
Number of subjects: 518
Study 35778674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 518
Study 35778703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum supernatant (SPU)
Number of subjects: 71
Study 35778703 — intervention group
Group type: COMPARATOR
Intervention: Plasma (PLA)
Number of subjects: 71
Study 35778757 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectric computer interface (MyoCI) training for 6 weeks
Number of subjects: 32
Study 35778956 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway replacement using stented aortic matrices
Number of subjects: 35
Study 35779080 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for colorectal cancer
Number of subjects: 0
Study 35779080 — intervention group
Group type: COMPARATOR
Intervention: Systematic clinical auditing activity
Number of subjects: 0
Study 35779081 — intervention group
Group type: EXPERIMENTAL
Intervention: Index surgery for traumatic fistulas (iatrogenic and obstetric)
Number of subjects: 55
Study 35779081 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated operations for traumatic fistulas (iatrogenic and obstetric)
Number of subjects: 55
Study 35779081 — intervention group
Group type: EXPERIMENTAL
Intervention: Index surgery for inflammatory fistulas (Crohn's disease, cryptoglandular infection, and anastomotic leakage)
Number of subjects: 55
Study 35779081 — intervention group
Group type: EXPERIMENTAL
Intervention: Final follow-up for inflammatory fistulas (Crohn's disease, cryptoglandular infection, and anastomotic leakage)
Number of subjects: 55
Study 35779081 — intervention group
Group type: EXPERIMENTAL
Intervention: Index surgery for others (radiation damage and unknown etiology)
Number of subjects: 55
Study 35779081 — intervention group
Group type: EXPERIMENTAL
Intervention: Final follow-up for others (radiation damage and unknown etiology)
Number of subjects: 55
Study 35779081 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealed patients
Number of subjects: 55
Study 35779095 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent antigen-KLH plus OPT-821 vaccine construct and bevacizumab
Number of subjects: 21
Study 35779166 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation (HNS)
Number of subjects: 227
Study 35779166 — intervention group
Group type: COMPARATOR
Intervention: Positive airway pressure (PAP)
Number of subjects: 227
Study 35779511 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxification (3-week inpatient)
Number of subjects: 30
Study 35779659 — intervention group
Group type: EXPERIMENTAL
Intervention: TXR 140 μg
Number of subjects: 99
Study 35779659 — intervention group
Group type: EXPERIMENTAL
Intervention: TXR 200 μg
Number of subjects: 99
Study 35779659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 35779669 — intervention group
Group type: EXPERIMENTAL
Intervention: Caribbean Hispanic/Latinx (CHL)
Number of subjects: 598
Study 35779669 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerto Ricans (PR)
Number of subjects: 598